| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8222462 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 6 Pages |
Abstract
We have demonstrated that Genexol-PM is more effective than Taxol as a radiosensitizer in the preclinical setting and holds high potential for clinical translation. Our data support the clinical evaluation of Genexol-PM in chemoradiation therapy for NSCLC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michael E. PhD, Natalie D. BS, Manish PhD, Edina C. BS, Rohit BS, Dominic T. MPH, Andrew Z. MD,